Detalhe da pesquisa
1.
A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas.
Blood
; 138(26): 2828-2837, 2021 12 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-34653242
2.
Carfilzomib and dexamethasone induction with lenalidomide, clarithromycin and dexamethasone consolidation and lenalidomide maintenance for newly diagnosed multiple myeloma.
Am J Hematol
; 96(12): 1554-1562, 2021 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34424561
3.
Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma.
J Clin Oncol
; 39(28): 3109-3117, 2021 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34170745